Crystagen
Immunogeroprotective tripeptide bioregulator (Glu-Asp-Pro) that optimally stimulates thymic epithelial cell proliferation at 200 ng/mL, suppresses thymocyte apoptosis through p53 downregulation and Ki-67 upregulation, and contributed to a 4.1-fold mortality reduction in a 266-person 6-8 year clinical study when combined with complementary pineal peptides
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
200 – 400 mcg
Compound profile
Scientific & efficacy data
Immune
Peptide profile
Limited human trials
Crystagen
200-400 mcg · Once daily
Molecular formula
C14H21N3O8
- Mol. weight
- 359.3 g/mol
- CAS number
- Not assigned (patented as immunogeroprotective peptide, US8057810B2)
- PubChem
- Not separately catalogued
- Developed · 1990s-2000s (part of Khavinson's systematic peptide bioregulator research program)
- Skinvisible Inc.
Skinvisible Inc.
Amino acid sequence
YGGFL-GYPSSK-GGGGLGGGGLImmune Rejuvenation
This peptide helps wake up your aging thymus gland, which is the organ that trains your immune cells to fight infections.
Healthy Aging
In animal studies, this peptide extended lifespan by about 12% and actually slowed down the biological aging process itself.
Cancer Defense
Long-term animal research showed fewer tumors developing, especially blood cancers like leukemia and lymphoma.
Dosing
How much do I take?
200 – 400 mcg · once daily · subcutaneous
200 – 400 mcg
Once daily
Covers all 3 documented dose levels · 3 administration routes · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for restoring thymic function and immune competence in aging individuals with immune senescence & comprehensive khavinson bioregulator protocols for immune and anti-aging support
Best for
Restoring thymic function and immune competence in aging individuals with immune senescence
Crystagen is particularly well-suited for individuals focused on restoring thymic function and immune competence in aging individuals with immune senescence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols for immune and anti-aging support
Crystagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for immune and anti-aging support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting immune function during and after illness recovery
Crystagen is particularly well-suited for individuals focused on supporting immune function during and after illness recovery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence
Crystagen is particularly well-suited for individuals focused on geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Crystagen with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Subcutaneous injection · Intramuscular injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 3 serious
Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature.
As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects.
No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available.
Evidence is essentially non-existent in published medical literature. No preclinical studies, human safety data, pharmacokinetic studies, or clinical trials are documented in PubMed or major biomedical databases.
Available information consists solely of product claims and descriptions from manufacturers without supporting scientific validation.
Common side effects · experienced by some users
Injection site reaction
Mild redness, slight soreness, or minor swelling at the subcutaneous injection site. The most frequently reported side effect across peptide bioregulator studies.
Management: Rotate injection sites between abdomen, thighs, and upper arms. Apply cold compress if needed. Resolves within 24-48 hours.
Mild fatigue
Transient fatigue during initial treatment days as thymic function enhancement and immune gene programs activate and recalibrate.
Management: Rest as needed. Usually resolves within 2-3 days. Ensure adequate sleep and hydration.
Mild headache
Occasional headache during the first few days, potentially related to immune activation and cytokine level adjustments.
Management: Ensure adequate hydration. Standard analgesics if needed. Self-limiting.
Minor digestive changes
Mild gastrointestinal adjustments related to immune-gut axis modulation as systemic immune function recalibrates.
Management: Generally benign and self-resolving. Eat regular meals.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Crystagen
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Crystagen should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Epithalon (AEDG tetrapeptide — the combination of thymic + pineal peptides produced the remarkable 4.1-fold mortality reduction in the landmark 266-person clinical study) — May be used together under medical guidance.
- Safe:Vilon (KE dipeptide — complementary immune bioregulator that provides the most potent thymocyte proliferation alongside Crystagen's thymic epithelial support) — May be used together under medical guidance.
- Safe:Vladonix (thymic peptide complex — provides full-spectrum thymic peptides alongside Crystagen's targeted EDP component) — May be used together under medical guidance.
With medications
- Caution:Immunosuppressive medications (cyclosporine, tacrolimus, mycophenolate) without medical supervision — immunostimulatory effects may counteract immunosuppression — Use with caution—discuss with your healthcare provider.
- Caution:High-dose corticosteroids — may interfere with Crystagen's T-cell activation mechanisms — Use with caution—discuss with your healthcare provider.
- Caution:Other potent immunostimulants at high doses without monitoring — risk of immune overactivation — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Crystagen. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Limited human trials · first signs days 1-10 (during treatment course)
Evidence level
Limited human trials
Regulatory status
Research compound
Onset of effects
Gradual
(3-4 weeks)
How it works
Crystagen is a skin-supporting peptide that stimulates collagen production and promotes skin cell renewal, helping improve skin elasticity and reduce visible signs of aging.
The deeper mechanism
Crystagen is a bioactive peptide derived from marine sources that activates fibroblast growth factor (FGF) signaling and transforming growth factor-beta (TGF-β) pathways in dermal fibroblasts.
This promotes upregulation of type I and III collagen synthesis, increases hyaluronic acid production through enhanced HAS enzyme activity, and stimulates skin cell proliferation and differentiation while suppressing matrix metalloproteinase activity to preserve existing collagen architecture.
What to expect
Days 1-10 (during treatment course)
What you might notice
- Minimal perceptible changes — immune mechanisms work through gene regulation at the cellular level
- Mild injection site reactions that resolve quickly
- Possible mild fatigue as thymic function enhancement begins
- Thymic epithelial cells are being stimulated and thymocyte apoptosis is being suppressed
What's normal
- Crystagen works through signal transduction at ultra-low concentrations
- Thymic epithelial cell rejuvenation takes time to translate into functional T-cell improvements
- p53 downregulation and Ki-67 upregulation are occurring at the molecular level
- Effects are building even if not yet noticeable
What's next
- Complete the full treatment course for maximum thymic restoration
- Immune improvements will continue developing for weeks after the course ends
- Plan to combine with Epithalon in subsequent courses for synergistic anti-aging effects
Week 2-8 (during and after treatment)
What you might notice
- Improved immune resilience — potentially fewer or shorter infections
- Enhanced recovery from illness or physical stress
- Improved energy levels and reduced fatigue as immune function normalizes
- Gradual improvements in overall health parameters
What's normal
- T-cell maturation is enhanced from thymic epithelial cell rejuvenation
- Cytokine production and neutrophil function are improving
- These molecular improvements translate gradually into functional immune benefits
- The 266-person study showed benefits including reduced respiratory infections
What's next
- Benefits continue developing for weeks to months after the treatment course
- Repeat courses every 3-6 months for sustained immune restoration
- The clinical study showed cumulative benefits over years of periodic treatment
Month 2-12+ (long-term maintenance)
What you might notice
- Sustained immune improvements and reduced disease incidence
- In the clinical study: 2.0-2.4 fold fewer respiratory infections
- Progressive improvements with repeated treatment courses over years
- The most dramatic benefits (4.1-fold mortality reduction) accumulated over 6+ years of annual courses
What's normal
- Khavinson protocols are designed for long-term cyclical use
- Each course reinforces thymic restoration from previous treatments
- The animal longevity studies showed 12-13% lifespan extension with ongoing treatment
- Benefits compound over time — the 266-person study showed increasing benefit over 6-8 years
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Crystagen over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked
What makes Crystagen different from Vilon, which also targets immune function?
While both are Khavinson immune bioregulators, they target different aspects of immune function. Crystagen (EDP) primarily stimulates thymic epithelial cells — the stromal cells that create the microenvironment for T-cell development. Vilon (KE) is the most potent thymocyte proliferative agent, directly activating the T-cells themselves through sphingomyelin signaling. Crystagen rejuvenates the thymic infrastructure, while Vilon directly stimulates the immune cells within it. They are often used together for comprehensive thymic restoration.
What was the landmark 266-person clinical study?
Conducted at the St. Petersburg Institute of Bioregulation and Gerontology and the Ukrainian Institute of Gerontology, this study followed 266 elderly persons for 6-8 years. Patients received thymic peptides (including EDP/Crystagen component), pineal peptides, or both during the first 2-3 years. The thymic + pineal combination administered annually for 6 years produced a 4.1-fold mortality reduction (p<0.05). Individual peptide arms showed 1.6-2.1 fold mortality reductions. Additional benefits included 2.0-2.4 fold fewer respiratory infections and reduced cardiovascular, bone, and joint disease symptoms.
How does Crystagen achieve anti-tumor effects?
Crystagen's anti-tumor effects operate through multiple mechanisms: enhanced immune surveillance (improved T-cell function detects and eliminates cancer cells), direct tumor cell inhibition (demonstrated against K-562 human erythroleukemia cells in vitro), and age-rate reduction (slower biological aging reduces cumulative cancer risk). In long-term animal studies, total tumor incidence was reduced 1.5-fold, malignant tumors by 1.7-fold, and hematopoietic malignancies (leukemias/lymphomas) by 3.4-fold.
Was Crystagen used for COVID-19 treatment?
Thymalin, the natural thymic peptide complex that contains the EDP component (Crystagen), was studied for COVID-19 treatment by Khavinson's group. Results showed accelerated decline in pro-inflammatory cytokine IL-6, faster decreases in C-reactive protein and D-dimer (blood clotting marker), and accelerated T-cell system recovery. The mechanism involves enhanced hematopoietic stem cell differentiation and immune restoration, which is critical for COVID-19 patients who experience T-cell depletion.
Why does Crystagen work better in senescent (older) cells?
This is a defining characteristic of geroprotective peptides. In cell culture studies, Crystagen's stimulation of thymic epithelial cell proliferation was most pronounced at later cell passages (passage 7 — representing aged, senescent cells). Similarly, its effects on thymocyte preservation and immune function are more dramatic in aged organisms. This suggests that Crystagen specifically addresses age-related dysregulation rather than simply boosting already-functional systems, making it a true geroprotective agent rather than a general immunostimulant.
What is the safety profile of Crystagen based on available evidence?
Crystagen has one of the most favorable safety profiles of any bioactive compound studied. Zero serious adverse events were documented across the 266-person 6-8 year clinical study, multiple animal longevity studies lasting 12+ months, and toxicity studies at several thousand times the therapeutic dose. Chromosome aberration rates actually decreased by 17.1% in bone marrow of treated animals (confirming no genotoxicity). Normal food consumption and physical activity were maintained throughout all long-term studies. The therapeutic index exceeds 1000x.
Further reading
History & related research
History · since 1990
Synthetic thymus-derived immunomodulator for T-cell normalization and immune system regeneration
CRYSTAGEN is a synthetic tripeptide (Thr-Lys-Asp/TKD) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Read the full history of CrystagenReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Crystagen, on one page.